For what it's worth, Clinical Trials Rundown in order of Estimated Completion Date.....Yes, it will be trashed buy some, but it is what it is....One more data point to consider.
Trial Identifier: NCT02406508
Study Title: Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Condition: Hepatocellular Carcinoma (HCC) (Phase 2)
Actual Start Date: October 2014
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Estimated Completion Date: September 2017 (Phase 2)??? My notes
Recruitment Status: Recruiting (Phase 3)??? My notes
Trial Identifier: NCT02415036
Study Title: Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Condition: Hepatocellular Carcinoma (Phase 2), Intrahepatic Cholangiocarcinoma (Phase 2)
Actual Start Date: June 2014
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Estimated Completion Date: February 2018
Recruitment Status: Recruiting
Trial Identifier: NCT03266042
Study Title: Registry Protocol-Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Condition: Hepatic Malignant Neoplasm Primary Non-Resectable (Observational)
Actual Start Date: January 14, 2016
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Estimated Completion Date: February 2019
Recruitment Status: Recruiting
Trial Identifier: NCT02678572
Study Title: Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)
Condition: Melanoma, Ocular (Phase 3)
Actual Start Date: January 2015
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Estimated Completion Date: June 2019
Recruitment Status: Recruiting
Trial Identifier: NCT03086993
Study Title: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Condition: Bile Duct Cancer (Phase 2), Intrahepatic Cholangiocarcinoma (Phase 3)
Anticipated Start Date: December 2017
Estimated Primary Completion Date: January 2023 (Final data collection date for primary outcome measure)
Estimated Completion Date: May 2023
Recruitment Status: Not Yet Recruiting
